文献速递白血病

维奈克拉联合阿扎胞苷或地西他滨治疗新诊断急性髓系白血病:1b期研究长期随访

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
PubMed 文献 · Am J Hematol · 2020-11-10

该分析报告了维奈克拉400mg联合阿扎胞苷或地西他滨治疗不适合强化疗的新诊断急性髓系白血病患者的长期随访结果。中位随访时间分别为29个月和40个月,联合阿扎胞苷组CR/CRi率为71%,联合地西他滨组为74%。两组中位OS分别为16.4个月和16.2个月,支持该联合方案作为高效一线治疗。

要点

  • 维奈克拉联合阿扎胞苷或地西他滨在不适合强化疗的新诊断AML中显示高缓解率。
  • 联合阿扎胞苷组CR/CRi率71%,联合地西他滨组74%。
  • 常见≥3级不良事件包括发热性中性粒细胞减少、贫血、血小板减少和中性粒细胞减少。

核心结论

  • 维奈克拉联合低甲基化药物是不适合强化疗的新诊断AML患者的高效一线治疗。

研究设计与样本

  • 开放标签、非随机、多中心1b期试验,纳入不适合强化疗的新诊断成人AML患者。
  • 维奈克拉400mg联合阿扎胞苷75mg/m2(第1-7天)或地西他滨20mg/m2(第1-5天)。

主要发现

  • 联合阿扎胞苷组中位随访29个月,联合地西他滨组中位随访40个月。
  • 联合阿扎胞苷组CR/CRi率为71%,联合地西他滨组为74%。
  • 联合阿扎胞苷组中位CR/CRi持续时间21.9个月,联合地西他滨组15.0个月。
  • 联合阿扎胞苷组中位OS为16.4个月,联合地西他滨组为16.2个月。

关键数值与推荐

  • 联合阿扎胞苷组≥3级发热性中性粒细胞减少发生率39%,贫血30%,血小板减少25%,中性粒细胞减少20%。
  • 联合地西他滨组≥3级发热性中性粒细胞减少发生率65%,贫血26%,血小板减少23%,中性粒细胞减少10%。

临床怎么用

  • 对于不适合强化疗的新诊断AML患者,可考虑维奈克拉联合阿扎胞苷或地西他滨作为一线治疗。

局限性

  • 本研究为非随机1b期试验,样本量未报告,结论需进一步随机研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This analysis represents the longest-term follow-up for patients with acute myeloid leukemia (AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in an open-label, non-randomized, multicenter phase 1b trial of venetoclax with azacitidine (AZA; 75 mg/m2 ; days 1-7) or decitabine (DEC; 20 mg/m2 ; days 1-5). Endpoints included safety, response rates (complete remission [CR], CR with incomplete blood count recovery [CRi]), response duration and overall survival (OS). The median follow-up time was 29 and 40 months for patients treated with venetoclax plus AZA and DEC combinations, respectively. Key Grade ≥ 3 AEs (AZA and DEC) were febrile neutropenia (39% and 65%), anemia (30% and 26%), thrombocytopenia (25% and 23%), and neutropenia (20% and 10%). The CR/CRi rate was 71% for venetoclax plus AZA and 74% for venetoclax plus DEC. The median duration of CR/CRi was 21.9 months and 15.0 months, and the median OS was 16.4 months and 16.2 months, for venetoclax plus AZA and DEC, respectively. These results support venetoclax plus hypomethylating agents as highly effective frontline AML therapies for patients unfit for intensive chemotherapy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2020. PMID: 33119898. doi:10.1002/ajh.26039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。